Showing 261 - 280 results of 778 for search '"Prostate cancer"', query time: 0.07s Refine Results
  1. 261

    Prostate Cancer in a Male with Holt-Oram Syndrome: First Clinical Association of the TBX5 Mutation by Noel J. Aherne, Guhan Rangaswamy, Pierre Thirion

    Published 2013-01-01
    “…We report the first clinical case of prostate cancer in an individual with Holt Oram syndrome.…”
    Get full text
    Article
  2. 262

    Incidental Discovery of Hepatocellular Carcinoma on 18F-PSMA PET CT Performed for Prostate Cancer Reassessment by Lauren Hekman, Eva Napierkowski, Natalie C. Hartman, Jeffrey L. Ellis, Robert H. Wagner, Davide Bova, Maria M. Picken, Robert C. Flanigan

    Published 2023-01-01
    “…We describe the case of a 76-year-old male with a rising prostate-specific antigen (PSA) after definitive prostate cancer treatment and no prior liver pathology who was incidentally found to have HCC on 18F-PSMA PET.…”
    Get full text
    Article
  3. 263
  4. 264
  5. 265
  6. 266
  7. 267
  8. 268

    Potentials and Limitations of Real-Time Elastography for Prostate Cancer Detection: A Whole-Mount Step Section Analysis by Daniel Junker, Georg Schäfer, Friedrich Aigner, Peter Schullian, Leo Pallwein-Prettner, Jasmin Bektic, Wolfgang Horninger, Ethan J. Halpern, Ferdinand Frauscher

    Published 2012-01-01
    “…Objectives. To evaluate prostate cancer (PCa) detection rates of real-time elastography (RTE) in dependence of tumor size, tumor volume, localization and histological type. …”
    Get full text
    Article
  9. 269

    The Utilization of Gleason Grade as the Primary Criterion for Ordering Nuclear Bone Scan in Newly Diagnosed Prostate Cancer Patients by Chad W. M. Ritenour, John T. Abbott, Michael Goodman, Naomi Alazraki, Fray F. Marshall, Muta M. Issa

    Published 2009-01-01
    “…Utilization of nuclear bone scans for staging newly diagnosed prostate cancer has decreased dramatically due to PSA-driven stage migration. …”
    Get full text
    Article
  10. 270
  11. 271

    The Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage for Metastatic Prostate Cancer by Ahmet Kiper, Orhan Yiğitbasi, Abdurrahim Imamoglu, Can Tuygun, Celaleddin Turan

    Published 2005-01-01
    “…The changes in serum prostate-specific antigen (PSA) concentrations can be used as a prognostic factor in patients undergoing maximum androgen blockage for metastatic prostate cancer. A total of 149 patients followed in our department were classified into 4 groups on the basis of PSA changes: group 1, those with normalisation of PSA levels within the first 3 months; group 2, those with normalisation of PSA between months 3 and 6; group 3, those with a decrease in PSA, but not reaching normal range; group 4, those with no decrease. …”
    Get full text
    Article
  12. 272
  13. 273
  14. 274

    Targeting the CLK2/SRSF9 splicing axis in prostate cancer leads to decreased ARV7 expression by Jasper Van Goubergen, Miroslav Peřina, Florian Handle, Elisa Morales, Anika Kremer, Oliver Schmidt, Glen Kristiansen, Marcus V. Cronauer, Frédéric R. Santer

    Published 2025-02-01
    “…In advanced prostate cancer (PC), in particular after acquisition of resistance to androgen receptor (AR) signaling inhibitors (ARSI), upregulation of AR splice variants compromises endocrine therapy efficiency. …”
    Get full text
    Article
  15. 275
  16. 276
  17. 277
  18. 278

    Predicting the risk of bone metastases in patients with newly diagnosed prostate cancer - Development and validation of a nomogram model. by Wei Xu, Guoyu Zhu, Xiaoxiang Wang, Xuebing Yan, Fujun Wang, Shanyi Li, Wenji Li

    Published 2025-01-01
    “…<h4>Objectives</h4>The aim of this study was to develop and validate a nomogram model that predicts the risk of bone metastasis (BM) in a prostate cancer (PCa) population.<h4>Methods</h4>We retrospectively collected and analyzed the clinical data of patients with pathologic diagnosis of PCa from January 1, 2013 to December 31, 2022 in two hospitals in Yangzhou, China. …”
    Get full text
    Article
  19. 279
  20. 280

    High Intensity Focused Ultrasound versus Brachytherapy for the Treatment of Localized Prostate Cancer: A Matched-Pair Analysis by Fouad Aoun, Ksenija Limani, Alexandre Peltier, Quentin Marcelis, Marc Zanaty, Alexandre Chamoun, Marc Vanden Bossche, Thierry Roumeguère, Roland van Velthoven

    Published 2015-01-01
    “…To evaluate postoperative morbidity and long term oncologic and functional outcomes of high intensity focused ultrasound (HIFU) compared to brachytherapy for the treatment of localized prostate cancer. Material and Methods. Patients treated by brachytherapy were matched 1 : 1 with patients who underwent HIFU. …”
    Get full text
    Article